1. Plazomicin is associated with improved survival and safety compared to colistin in serious carbapenem-resistant Enterobacteriaceae (CRE) infections: results of the CARE Study;Connolly,2017
2. Evaluating once-a-day plazomicin versus meropenem for the treatment of complicated urinary tract infection and acute pyelonephritis: results from a phase 3 study (EPIC);Cloutier,2017
3. Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms;Castanheira;J Antimicrob Chemother,2018
4. Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae;Thwaites;Diagn Microbiol Infect Dis,2018
5. Pharmacokinetics (PK) of plazomicin in healthy adults;Seroogy,2017